Join the Oncology Voice Network. Join for Free
Motivation Means NOTHING…
Medical Science Liaisons discipline in Medical Affairs achieving goals personal growth strategies success in MSL roles

Motivation Means NOTHING…


Share This Article


Summary

In this episode, Tom Caravela delves into the crucial role of discipline for Medical Science Liaisons. He outlines a four-step process to help MSLs achieve their goals within Medical Affairs, emphasizing the importance of starting small and maintaining a zero-compromise mentality. Tom underscores the significance of discipline in driving success and personal growth. The episode wraps up with a call to action, inviting listeners to incorporate these strategies into their professional lives.

This SOLO episode features Tom Caravela, Managing Partner at The Carolan Group sharing his thoughts on WHY motivation means NOTHING and what it takes to find success and achieve your goals
Tom shares….

👉 WHY motivations means nothing
👉 What it takes to find consistent success
👉 The formula for consistency
👉 How to ACHIEVE and find success at the highest levels

Click for Source
Medical Science Liaisons, discipline in Medical Affairs, achieving goals, personal growth strategies, success in MSL roles

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Explore OVN